
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer.
prostate cancer
Adam Kibel, MD, chief of urology, Dana Farber Cancer Institute, Brigham and Women's Hospital, discusses how to properly treatpatients with bone metastases and what the goals of the treatments are.
Kibel cited both the STAMPEDE and CHAARTED trials, which showed the efficacy of docetaxel plus androgen deprivation therapy (ADT) in metastatic prostate cancer. The combination significantly improved overall survival (OS), which Kibel says is proof enough to implement docetaxel in patients with bone metastatic cancer.






